Terrence O Brien, MD
Cardiovascular Disease · Charleston, SCNPI 1578671525
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $340 of the $340 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, GE HealthCare. That places this record below the midpoint for cardiovascular disease clinicians in SC, where the typical reported total is $3,855.
Across 1 payment — averaging $340.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GE HealthCare$340
Across 107 payments — averaging $1490.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$64K
- Boehringer Ingelheim$30K
- Amgen$23K
- Boehringer Ingelheim Pharma GmbH & Co.kg$22K
- Boehringer Ingelheim International GmbH$15K
- AstraZeneca$6K
What the payments were for
- Consulting fees$340100%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GE HealthCare | 1 | $340 |
How this compares
$340 in reported general payments places this provider in the 10th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 235 | $227,982 |
| EntrestoSacubitril/Valsartan | 75 | $96,575 |
| XareltoRivaroxaban | 69 | $70,996 |
| JardianceEmpagliflozin | 34 | $36,939 |
| MultaqDronedarone Hcl | 28 | $30,215 |
| Repatha SureclickEvolocumab | 29 | $29,119 |
| Metoprolol Succinate | 296 | $5,329 |
| Atorvastatin Calcium | 259 | $3,484 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 64 | $3,250 |
| Ezetimibe | 62 | $2,232 |
| Amiodarone Hcl | 22 | $2,168 |
| Potassium Chloride | 30 | $1,115 |
| Losartan Potassium | 70 | $989 |
| Warfarin Sodium | 46 | $805 |
| Amlodipine Besylate | 94 | $778 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Charleston
- Robert BiedermanCharleston$775K
- Priyanka BhattacharyaCharleston$107K
- James SmithCharleston$64K
- Geetha PintoCharleston$51K
- Pamela MorrisCharleston$23K
- Ian LaxinaCharleston$21K
- William YarbroughCharleston$19K
- Minh TranCharleston$18K
- Troy BuntingCharleston$16K
- Samuel PowellCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.